We can’t show the full text here under this license. Use the link below to read it at the source.
Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data
More reports of vision problems linked to semaglutide use
AI simplified
Abstract
Semaglutide is associated with a 1.95 times higher reporting of vision impairment compared to other GLP-1 receptor agonists.
- Reporting odds ratios indicate semaglutide has significantly higher vision impairment reports compared to DPP-4 inhibitors (rOR 2.46) and SGLT2 inhibitors (rOR 3.89).
- Vision impairment reporting for semaglutide is also elevated compared to metformin (rOR 2.23) and phentermine (rOR 1.57).
- Orlistat shows a similar association with vision impairment (rOR 3.77) compared to semaglutide.
- Topiramate is noted as an exception, with a lower reporting odds ratio for vision impairment (rOR 0.30) compared to semaglutide.
- The findings suggest a need for further examination of the ocular safety of semaglutide in clinical settings.
AI simplified
Key numbers
1.95
Higher for Vision Impairment
for semaglutide vs. other
2.46
Increased vs. DPP-4 Inhibitors
for semaglutide vs. DPP-4 inhibitors
3.89
Increased vs. SGLT2 Inhibitors
for semaglutide vs. SGLT2 inhibitors